Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning
announced the creation of four new wholly-owned subsidiary companies: Lexaria
CanPharm Corp., a Canadian company that provides DehydraTECH technology and
other enhancements to the global cannabis industry; Lexaria Nicotine Corp., a
US company with a global license to offer DehydraTECH technology to the global
nicotine and tobacco industries; Lexaria Hemp Corp., a US company globally
licensed to provide DehydraTECH to the burgeoning hemp-based foods and
supplements industries; and Lexaria Pharmaceutical Corp., a US company
internationally authorized to license DehydraTECH to the pharmaceutical sector,
including pain relief, vitamins, hormone treatments, central nervous system
conditions and more. To greater engage with the separate customer bases and
business applications for each subsidiary, this new corporate structure enables
Lexaria to focus its future research, potential financing structures and
industry partnerships on options specifically suited for each new subsidiary.
The company also plans to use wholly-owned Poviva Tea Corp. to advance the
current ViPova Tea and Coffee consumer brands. In addition, Lexaria announced
that it has received $33,000 from the exercise of 330,000 options at the price of
$0.10 previously granted to a third party. The proceeds will be used for
general corporate purposes.
To view the full press release, visit http://ibn.fm/mKqcZ
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive patented
delivery technology that promotes healthier ingestion methods, lower overall
dosing and higher effectiveness of lipophilic active molecules. Lexaria has
multiple patents pending in over 40 countries around the world and has patents
granted in the USA and in Australia for utilization of its DehydraTECH™
delivery technology. Lexaria’s technology provides increases in intestinal
absorption rates; more rapid delivery to the bloodstream; and important
taste-masking benefits, for orally administered bioactive molecules including
cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs),
nicotine and other molecules. For more information, visit the company’s website
at www.LexariaBioscience.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment